DSM Announces SafeBridge(R) Potent Compound Safety Certification
PARSIPPANY, N.J., Aug. 5 /PRNewswire/ -- DSM Pharmaceutical Products has announced that their Greenville, North Carolina facility has received the( )Potent Compound Safety Certification from SafeBridge((R)) Consultants, Inc. headquartered in Mountain View, California. The Certification is for competency and proficiency in the safe handling of potent active pharmaceutical ingredients (APIs) and potent drug products, and applies to the site's potent sterile fill/finish production area, including the high containment fill/finish facility, and the associated quality control laboratories.
SafeBridge conducted a 60-element review of programs, procedures, containment and control of the active pharmaceutical ingredients at the company's site. This third party certification verifies performance with established criteria in management, evaluation, containment, control and communication elements of potent compound production operations. Elements of the program include on-site assessment of the potent compound manufacturing and laboratory areas and the associated equipment, training, and toxicology and industrial hygiene support.
Since program inception in 1999 eight organizations have achieved Potent Compound Safety Certification. The DSM North Carolina facility joins five other facilities actively involved in the SafeBridge((R)) Potent Compound Safety Certified program to date.
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com
Royal DSM N.V. - The Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
SafeBridge Consultants, Inc.
The premier occupational health and safety consulting firm to the pharmaceutical, biotechnology and fine chemical industry with offices in Mountain View, CA, New York, NY and Liverpool, UK. SafeBridge has provided the Potent Compound Safety Triangle(TM) of services in industrial hygiene, occupational toxicology and industrial hygiene analytical chemistry to over 400 business units worldwide and is a leader in recognizing, evaluating and controlling exposures to potent active pharmaceutical ingredients and products. More information www.safebridge.com
For further information please contact:
DSM Pharmaceutical Products SafeBridge Consultants, Inc. David Linn John P. Farris, CIH Director of Marketing President and Chief Executive Officer DSM Pharmaceuticals, Inc. Tel: +1 650 961 4820 ext 229 Tel: +1 512 569 9322 Email: email@example.com Email: firstname.lastname@example.org
This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
Apr 22, 2013, 02:00 ET
DSM signs Master Supply Agreement with Eisai Inc.
Mar 05, 2013, 02:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.